Advanced search
Publication Cover
Acta Cardiologica Volume 70, 2015 - Issue 2
Submit an article Journal homepage
23
Views
5
CrossRef citations to date
0
Altmetric
Articles

Ranolazine enhances nicardipine-induced relaxation of alpha1-adrenoceptor-mediated contraction on isolated rabbit aorta

Christina Malavaki1Laboratory of Physiology, Dept. of Medicine, School of Health Sciences, University of Thessaly, Biopolis Larissa, Greece;Division of Nephrology, Medical School, University of Thessaly, Larissa, Greece
, Phd;,
Apostolia HatziefthimiouLaboratory of Physiology, Dept. of Medicine, School of Health Sciences, University of Thessaly, Biopolis Larissa, Greece
, Md;,
Stella S. DaskalopoulouDept. of Medicine, Divisions of Internal Medicine and Experimental Medicine, McGill University, McGill University Health Centre, Canada
, Md;,
Ioannis StefanidisDivision of Nephrology, Medical School, University of Thessaly, Larissa, Greece
, Md;,
Christina KaratzaferiMuscle Physiology & Mechanics Group, DPESS, University of Thessaly, Trikala, Greece.
, Phd; &
Isaac AidonidisLaboratory of Physiology, Dept. of Medicine, School of Health Sciences, University of Thessaly, Biopolis Larissa, GreeceCorrespondence[email protected]
, Md
Pages 157-162 | Received 18 Nov 2014, Accepted 11 Dec 2014, Published online: 23 May 2017

  • Paredes-Carbajal MC, Monsalvo I, Hernandez-Diaz C, Regla I, Demare P, Mascher D. Effects of ranolazine on vasomotor responses of rat aortic rings. Arch Med Res 2013: 44: 8–12.
  • Deng, CY, Kuang SJ, Rao F, Yang H, Fang XH, Shan ZX, Li XH, Zhou ZI, Lin QX, Yang M, Wu SL, Yu XY, Lin SG. Effect of ranolazine on rat intrarenal arteries in vitro. Eur J Pharmacol 2012; 683: 211–6.
  • Dhalla AK, Wang WQ Dow J, Shryock JC, Belardinelli L, Bhandari A, Kloner RA. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2009; 297: H1923–H1929.
  • Belardinelli L, Liu G, Smith-Maxwell C, Wang WQ El-Bizri N, Hirakawa R, Karpinski 5, Li CH, Hu L, Li XJ, Crumb W, Wu L, Koltun D, Zablocki J, Yao L, Dhalla AK, Rajamani 5, Shryock JC. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. J Pharmacol Exp Ther 2013; 344:23–32.
  • Morita N, Lee JH, Xie Y, Sovari A, Qu Z, Weiss JN, Karagueuzian HS. Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine. J Am Coll Cardiol 2011; 57:366–75.
  • Verrier RL, Kumar K, Nieminen T, Belardinelli L Mechanisms of ranolazine’s dual protection against atrial and ventricular fibrillation. Europace 2013; 15:317–24.
  • Simopoulos V, Tagarakis GI, Daskalopoulou SS, Daskalopoulos ME, Lenos A, Chryssagis K, Skoularingis I, Molyvdas PA, Tsilimingas NB, Aidonidis I. Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery. Angiology 2014; 65:294–97.
  • Allely MC, Brown CM, Kenny BA, Kilpatrick AT, Martin A, Spedding M. Modulation of alpha1-adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: protection by ranolazine. J Cardiovasc Pharmacol 1993; 21:869–73.
  • Zhao G, Walsh E, Shryock JC, Messina E, Wu Y, Zeng D, Xu X, Ochoa M, Baker SP, Hintze TH, Belardinelli L. Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs. J Cardiovasc Pharmacol 2011; 57:639–47.
  • Fort A, Cordaillat M, Thollon C, Salazar G, Mechaly, Villeneuve N, Vilaine JP, Richard 5, Virsolvy A. New insights in the contribution of voltage-gated Na(v) channels to rat aorta contraction. PLoS One 2009; 4: e7360.
  • Ho WS, Davis AJ, Chadha PS, Greenwood LA. Effective contractile response to voltage-gated Na + channels revealed by a channel activator. Am J Physiol Cell Physiol 2013; 304: C739–C747.
  • Chiou WF, Chou CJ, Liao JF, Sham AY, Chen CF. The mechanism of the vasodilator effect of rutaecarpine, an alkaloid isolated from Evodia rutaecarpa. Eur J Pharmaco11994; 257: 59–66.
  • Khazraei H, Mirkhani H, Purkhosrow A. Vasorelaxant effect of ranolazine on isolated normal and diabetic rat aorta: A study of possible mechanisms. Acta Physiol Hung 2013; 100: 153–62.
  • LedouxJ, Werner ME, Brayden JE, Nelson MT. Calcium-activated potassium channels and the regulation of vascular tone. Physiology 2006; 21: 69–78.
  • Martinsen A, Schakman 0, Verna X, Dessy C, Morel N. Myosin light chain kinase controls voltage-dependent calcium channels in vascular smooth muscle. Pf/ugers Arch 2014; 466:1377–89.
  • Chen L, Wang L, Xu B, Ni G, Yu L, Han B, Yu X, Wang K, Lai Y, Zhou 5, Zhu Q. Mechanisms of alpha1-adrenoceptor mediated QT prolongation in the diabetic rat heart. Life Sci 2009; 84: 250–6.
  • Parikh A, Mantravadi R, Kozhevnikov D, Roche MA, Ye Y, Owen U, Puglisi JL, Abramson JJ, Salama G. Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2. Heart Rhythm 2012; 9:953–60.
  • LovelockJD, Monasky MM, Jeong EM, Lardin HA, Liu H, Patel BG, Taglieri DM, Gu L, Kumar P. Pokhrel N, Zeng D, Belardinelli L, Sorescu D, Solaro RJ, Dudley SC. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res 2012; 110: 841–50.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
Novartis. Your partner in Heart Failure & Atherosclerosis >>

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.